Navigation Links
Advanced Life Sciences Applies for FDA Orphan Drug Designation for ALS-886 to Treat Acute Lung Injury
Date:11/18/2010

nts for ARDS.  Because infection is often the underlying cause of ARDS, appropriate antibiotic therapy is administered. There are approximately 150,000 cases of ARDS in the United States annually and the mortality rate is approximately 50%. Patients who survive ARDS will typically experience ongoing mild to moderate impairment of lung function, with poorer health-related quality of life after hospitalization compared to patients who were hospitalized without ARDS.  

About ALS-886

ALS-886 is a small molecule therapeutic that, in preclinical studies, has demonstrated efficacy in both scavenging existing free radicals and sequestering free iron. The goal of treatment with ALS-886 for ARDS will be to reduce the tissue damage brought about by the free radicals in the lungs. Previous animal toxicology studies have demonstrated the safety and benign side effect profile of ALS-886. This could prove beneficial in the use of the compound in the critical care setting. In addition, the mild safety profile shown in animal studies supports the possibility that ALS-886 could be used as a prophylactic. That is, it could be administered to individuals who are at high risk of developing ARDS, such as patients suffering from sepsis or severe trauma, in order to prevent the underlying condition from leading to ARDS. ALS-886 may also have applicability for other conditions in which free radicals cause tissue damage, such as ischemic stroke and myocardial infarction. An open IND is in place to start Phase I clinical trials.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza™, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... and Volcano Corporation (NASDAQ: VOLC ), a global ... today announced that they have entered into a definitive merger ... offer to acquire all of the issued and outstanding shares ... equity purchase price of USD 1 billion (approx. EUR 800 ...
(Date:12/17/2014)... December 17, 2014 Revenue and earnings ... on research and development In the past 2013/14 ... by two percent to EUR 4.287 billion (last year: EUR ... 14 percent to EUR 360 million. "Overall, 2013/14 was a ... Michael Kaschke , President and CEO of Carl Zeiss AG. ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... , WARSAW, Ind. , March 11 Zimmer ... in musculoskeletal care, will celebrate the 25th anniversary of the ...  The Natural Knee system offers a complete range of ...  Published clinical results show survivorship of the Natural Knee ...
... , March 11 Watson Pharmaceuticals, Inc. ... Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 ... formulation of TRELSTAR®, a proven, simple and effective palliative ... launch, TRELSTAR® 22.5 mg is the first and only ...
Cached Medicine Technology:Zimmer Natural Knee Celebrates 25 Years of Excellence 2Zimmer Natural Knee Celebrates 25 Years of Excellence 3Zimmer Natural Knee Celebrates 25 Years of Excellence 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8
(Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
(Date:12/20/2014)... OH (PRWEB) December 20, 2014 ... contend they suffered uncontrollable bleeding and other serious ... Court, Eastern District of Louisiana for coordinated pretrial proceedings, ... on Multidistrict Litigation (JPML) issued an order Friday to ... actions pending in 22 federal courts to the Louisiana ...
(Date:12/19/2014)... 2014 It’s very easy to become overwhelmed ... is put to the wayside until Christmas and the New ... travel “itch” and that burning desire to just escape it ... their journey to Telluride with a no-fuss, affordable package. Montrose ... from the resort, and ensure that all accommodations are met. ...
(Date:12/19/2014)... Branson, Missouri (PRWEB) December 19, 2014 ... a new official world record -- for the first time ... most prestigious record book, Guinness World Records 2015, listing the ... Steepest Wooden Roller Coaster. In additional awards announced this week, ... to See Christmas Lights in the US,” USA Today’s 10Best ...
(Date:12/19/2014)... Abilene, TX (PRWEB) December 20, 2014 ... XC, a new injectable filler from respected cosmetic brand ... can occur naturally with age. The Medspa at Hendrick ... new development in skin care technology to its clients. ... filler gel to be FDA-approved to treat the mid-face ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... that increased levels of C-reactive protein in the blood ... ,This finding could lead to new and improved ... as developing drugs that suppress inflammation to improve the ... ,The Mayo Clinic research report appears online and in ...
... The use of computers is hardly limited to what takes ... Here is the kind of utility that has the potential ... based hospital has // already started to perform knee replacement ... the surgery is said to be associated with a reduction ...
... A recent broadcast by BBC , looked into antibiotic resistance ... findings of the agencies laboratory which carried out the testing ... , ,Using these results the programme asserted various ... resistant bacteria found in the chicken samples and human illness. ...
... in the latest online edition of The Lancet Neurology says ... having multiple sclerosis is nothing but a myth. Birth order ... the disease, nor does their family size // have any ... that both environmental and genetic factors have a role in ...
... a combination of surgery and radiation yields better mobility, ... compression. //, ,Metastatic epidural spinal cord compression (MESCC) ... in 5 to 14 percent of cancer patients. Standard ... after which only 50 percent of patients are able ...
... pregnancies have recently also been under intense scrutiny to ... diseases (e.g. Gonorrhea and 25 other related conditions) and ... the most famous lover of all, Casanova in the ... and for protection against infection. The question now is ...
Cached Medicine News:Health News:Artery Stiffness Linked To Increasing Levels Of C-reactive protein 2Health News:Ways Of Tackling Antibiotic Resistance 2Health News:"An Armour against pleasure, and a cobweb against infection" – Has the condom withstood the test of time 2Health News:"An Armour against pleasure, and a cobweb against infection" – Has the condom withstood the test of time 3Health News:"An Armour against pleasure, and a cobweb against infection" – Has the condom withstood the test of time 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: